tirzepatide is a glp 1 Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Beyond glycemia: Comparing tirzepatide to

Compared to patients treated for diabetes with a non-GLP-1 medication, GLP-1 use was associated with 14% reduced risk of developing any substance use disorder

This concentration means smaller injection volumes (5 units for 0.25mg), which some find more comfortable

Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are now mainstream, with patients often asking about them before clinicians bring them up

Taking naltrexone and GLP-1s simultaneously could provide the following benefits: Reduced "reward" of drinking in the moment with naltrexone and lower baseline interest in alcohol with GLP-1 semaglutide

- Stay hydrated and eat light Drinking enough water supports your skins natural functions and can help reduce excess oil production

After losing 17.3% on semaglutide over 68 weeks, participants discontinued everything